Systems, devices, and methods may control total particulate matter (TPM) production based on air flow rate and TPM density. TPM density is a TPM production rate per flow rate of gas through an aerosol-generating device. The systems, devices, and methods may measure, or sample, air flow during a puff or draw on an aerosol-generating device. The aerosol-generating device may, in turn, adjust the production of the TPM based on the measured air flow rate and a selected, or desired, TPM density, which may be pre-set in the device and/or subsequently set as desired.

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

A nasal fluid-spray device having: a reservoir containing at least one dose (D) of fluid; and a dispenser system that, each time the device is actuated, sprays a dose (D) of fluid through a spray orifice, generating a spray that extends axially from the spray orifice. The device further includes a generator system for generating a secondary flow, which generator system is actuated simultaneously with the dispenser system, the secondary flow generator system having a secondary flow channel provided with an outlet orifice, the outlet orifice arranged downstream from the spray orifice, and the secondary flow extending from the outlet orifice along an axis (B) that forms an angle (α) relative to the axis (A) of the spray and that intersects the axis (A), thereby deforming and/or deflecting the spray.

A system for conducting inhalation studies includes an inhalation exposure chamber and an aerosol delivery line connected to the inhalation exposure chamber. The aerosol delivery line is configured to produce a bi-directional and symmetrical presentation of aerosol to the inhalation exposure chamber. A laminar flow element is configured to create an ante-chamber where complete and turbulent mixing of the aerosol occurs. A radial exhaust and the laminar flow element enable laminar flow of the aerosol through the inhalation exposure chamber.

Systems and methods are provided for generating and applying artificial tear film layers to a cornea surface. An example method includes forming an artificial tear film that is optically transparent, ultra-thin, and smoothly conforming to cornea surface. The artificial tear film includes a lipid layer that prevents evaporation of moisture from the cornea (e.g., from the underlying aqueous layer of the artificial tear film, and/or from the natural tear film on the cornea, etc.). A dispenser, such as an atomizer/nebulizer/micronizer, can be used to generate and applying the artificial tear film layers, especially the lipid layer, with reduced dispensing volume and average droplet size, etc., such that the deposit thickness of the artificial tear film layers remains thin and better spreads and conforms to the surface of the cornea, as compared to the results of conventional eye droppers dispensing conventional artificial tears.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

A device for generating a condensation aerosol includes (a) vaporization chamber having an upstream first inlet and a downstream outlet; (b) a heater element in the vaporization chamber between the upstream first inlet and the downstream outlet; (c) an airflow path in fluid communication with the vaporization chamber, wherein the airflow path comprises a second inlet configured to permit a substantially laminar flow of air into the airflow path, wherein the second inlet is downstream of the heater element; and (d) the device having components or apparatus on or in the device for changing air flow in the vaporization chamber. Changing the air flow in the vaporization chamber may be used to change the particle size of a condensation aerosol produced in the vaporization chamber, and/or to change the amount of visible vapor emitted from the device.

An atomizing nozzle structured particularly for nasal therapy. Preferred embodiments include a 2-piece atomizing nozzle structured to couple with luer-locking structure carried by a syringe. Such an atomizing nozzle includes a nasal stopper and a stem. A preferred nasal stopper includes a distal tip sized for insertion into a nostril of a human child, with a proximal shield portion being structured to resist over-insertion of a discharge orifice into the nostril. A nasal stopper desirably provides a centering function to urge the discharge orifice away from a nasal wall. One operable stem is structured to couple with the stopper and desirably carries unitary thread structure at a proximal end. A second operable stem is structured as a unitary part of the nasal stopper and also desirably carries unitary thread structure at a proximal end. Certain embodiments may also include spacer structure configured to reduce a dead volume inside the atomizing nozzle. Other embodiments may also include spacer structure configured to reduce dead volume inside a syringe that is coupled to the atomizing nozzle.

A powder aerosolization apparatus comprises a housing comprising an outlet adapted to be inserted into a user's mouth and one or more bypass air openings. A receptacle support within the housing supports a receptacle containing a powder pharmaceutical formulation. A puncturing mechanism within the housing creates in the receptacle one or more inlet openings and one or more powder outflow openings, wherein the powder outflow openings have a total area of from 0.2 mm.sup.2 to 4.0 mm.sup.2. Upon a user's inhalation through the outlet, air flows through the one or more bypass air openings and through the receptacle to aerosolize the powder pharmaceutical formulation in the receptacle. In one version, the relative flow parameters between the flow through the one or more bypass openings and the one or more powder outflow openings are selected so that flow of aerosolized pharmaceutical formulation does not occur until a predetermined inhalation flow rate is achieved.

This non-combusting flavor inhaler is provided with a first flow path which is disposed downstream of a vaporizer unit, and, as an aerosol flow path, a second flow path which is disposed downstream of the first flow path. The second flow path houses a flavor source for imparting flavor to an aerosol. In order to suppress unevenness of aerosol flow in the second flow path, an aerosol flow adjustment chamber for adjusting flow of the aerosol supplied from the first flow path is provided between the first flow path and the second flow path.